China’s SIMM, French Drugmaker Servier To Collaborate On Anti-Tumor Medicine R&D

Shanghai Institute of Materia Medica (SIMM) and French pharmaceutical company Servier Laboratories signed an agreement on the R&D of targeted antitumor drug candidate lucitanib. Under the agreement, ShangHai HaiHe Pharmaceutical Co., Ltd., which is under SIMM, and Servier’s China arm will jointly conduct clinical trials and biomarker studies of lucitanib in China, including indications in the Chinese population. They will also co-register and co-declare the drug’s certificate. In September 2012, Servier was granted worldwide rights (except in China, the U.S. and Japan) for lucitanib, which is hailed for its obvious efficacy in breast cancer treatment, (Click Here For More - Chinese Language